Addressing the Neuroprotective Actions of Coffee in Parkinson’s Disease: An Emerging Nutrigenomic Analysis

Lee, Lai Kuan; Rodzi, Nur Anis Raihana Mhd

doi:10.3390/antiox11081587

Cited by 6 publications

(4 citation statements)

References 89 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies support the neuroprotective effects of coffee and tea on PD through caffeine 42 , 43 . As an antagonist of the adenosine A2a receptor, caffeine could enhance dopamine transmission 44 .…”

Section: Discussionmentioning

confidence: 98%

Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank

Huang,

Chen,

Wang

et al. 2024

npj Parkinsons Dis.

View full text Add to dashboard Cite

Substantial evidence shown that the age at onset (AAO) of Parkinson’s disease (PD) is a major determinant of clinical heterogeneity. However, the mechanisms underlying heterogeneity in the AAO remain unclear. To investigate the risk factors with the AAO of PD, a total of 3156 patients with PD from the UK Biobank were included in this study. We evaluated the effects of polygenic risk scores (PRS), nongenetic risk factors, and their interaction on the AAO using Mann–Whitney U tests and regression analyses. We further identified the genes interacting with nongenetic risk factors for the AAO using genome-wide environment interaction studies. We newly found physical activity (P < 0.0001) was positively associated with AAO and excessive daytime sleepiness (P < 0.0001) was negatively associated with AAO, and reproduced the positive associations of smoking and non-steroidal anti-inflammatory drug intake and the negative association of family history with AAO. In the dose-dependent analyses, smoking duration (P = 1.95 × 10−6), coffee consumption (P = 0.0150), and tea consumption (P = 0.0008) were positively associated with AAO. Individuals with higher PRS had younger AAO (P = 3.91 × 10−5). In addition, we observed a significant interaction between the PRS and smoking for AAO (P = 0.0316). Specifically, several genes, including ANGPT1 (P = 7.17 × 10−7) and PLEKHA6 (P = 4.87 × 10−6), may influence the positive relationship between smoking and AAO. Our data suggests that genetic and nongenetic risk factors are associated with the AAO of PD and that there is an interaction between the two.

show abstract

Section: Discussionmentioning

confidence: 98%

Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank

Huang,

Chen,

Wang

et al. 2024

npj Parkinsons Dis.

View full text Add to dashboard Cite

show abstract

“…In addition, there are life style and behavioural factors which can increase Parkinson's disease risk, such as head trauma [78], mental illness [75] and the consumption of dairy products [79], or decrease Parkinson's disease risk, such as exercise [80], tobacco [81] and coffee [82]. There are also a number of diseases and conditions that are known to increase the risk of developing Parkinson's disease.…”

Section: Potential Causesmentioning

confidence: 99%

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Bicknell,

Liebert,

Herkes

2024

JPM

View full text Add to dashboard Cite

Parkinson’s disease is the second most common neurodegenerative disease and is increasing in incidence. The combination of motor and non-motor symptoms makes this a devastating disease for people with Parkinson’s disease and their care givers. Parkinson’s disease is characterised by mitochondrial dysfunction and neuronal death in the substantia nigra, a reduction in dopamine, accumulation of α-synuclein aggregates and neuroinflammation. The microbiome–gut–brain axis is also important in Parkinson’s disease, involved in the spread of inflammation and aggregated α-synuclein. The mainstay of Parkinson’s disease treatment is dopamine replacement therapy, which can reduce some of the motor signs. There is a need for additional treatment options to supplement available medications. Photobiomodulation (PBM) is a form of light therapy that has been shown to have multiple clinical benefits due to its enhancement of the mitochondrial electron transport chain and the subsequent increase in mitochondrial membrane potential and ATP production. PBM also modulates cellular signalling and has been shown to reduce inflammation. Clinically, PBM has been used for decades to improve wound healing, treat pain, reduce swelling and heal deep tissues. Pre-clinical experiments have indicated that PBM has the potential to improve the clinical signs of Parkinson’s disease and to provide neuroprotection. This effect is seen whether the PBM is directed to the head of the animal or to other parts of the body (remotely). A small number of clinical trials has given weight to the possibility that using PBM can improve both motor and non-motor clinical signs and symptoms of Parkinson’s disease and may potentially slow its progression.

show abstract

“…The Arabian coffee (Coffea arabica) plant is a member of the Coffea genus, which belongs to the family Rubiaceae. Coffee has been investigated for its protective effect against many chronic diseases, such as cancer [ 26 ], liver diseases, Parkinson’s disease [ 27 ], and diabetes mellitus T2. Regular consumption of coffee can help maintain liver function activity, with a reduction in the risk of chronic liver disease [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Nanoemulsions of Phoenix dactylifera L. (Decaffeinated) and Coffea arabica L. Extracts as a Novel Approach for the Treatment of Carbon Tetrachloride-Mediated Liver Fibrosis

Alamri,

Bayomy,

Hussein

et al. 2024

Antioxidants

View full text Add to dashboard Cite

Liver fibrosis is a condition characterized by the excessive buildup of scar tissue in the liver. This scarring occurs as a result of chronic liver damage, often caused by conditions such as hepatitis, alcohol abuse, certain metabolic disorders, genetic abnormalities, autoimmunity, and noninfectious diseases such as fatty liver which leads to liver fibrosis. Nanoparticles have gained attention in recent years as potential therapeutic agents for liver fibrosis. They offer unique advantages due to their small size, large surface area, and ability to carry drugs or target specific cells or tissues. Studies have suggested that nanoemulsions may enhance drug delivery systems, enabling targeted drug delivery to specific sites in the liver and improving therapeutic outcomes. In this study, we explore the protective and therapeutic values with phytochemical profiling of the used agro-wastes decaffeinated palm date seeds (Phoenix dactylifera L., PSC) coffee and caffeinated Arabic coffee seeds (Coffea arabica L.; ACS). Both ACS and PSC extracts were converted into nanoemulsion (NE) forms using the oleic acid/Tween 80 system, which was recruited for the purpose of treating a rat model with liver fibrosis. Transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to record the sizes, morphologies, hydrodynamic diameters, and ζ-potentials of the prepared NE-ACSE and NE-PSCE. Accordingly, the NE-ACSE and NE-PSCE imaged via TEM and their ζ-potentials were recorded at 20.7, 23.3 nm and −41.4, −28.0 mV, respectively. The antioxidant properties were determined with a DPPH scavenging assay. The synthesized NE-PSCE and NE-ACSE were employed to treat a rat model with CCl4-induced liver fibrosis, to estimate the role of each emulsion-based extract in the treatment of liver fibrosis through recording inflammatory parameters, liver functions, antioxidant enzymes, and histopathological analysis results. The nanoemulsion forms of both ACSE and PSCE provided significant increases in antioxidant enzymes, reducing inflammatory parameters, compared to other groups, where liver functions were decreased with values close to those of the control group. In conclusion, both nanoemulsions, ACSE and PSCE, provided a new avenue as therapeutic approaches for liver diseases, and further studies are encouraged to obtain maximum efficiency of treatment via the combination of both extracts.

show abstract

Addressing the Neuroprotective Actions of Coffee in Parkinson’s Disease: An Emerging Nutrigenomic Analysis

Cited by 6 publications

References 89 publications

Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank

Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Nanoemulsions of Phoenix dactylifera L. (Decaffeinated) and Coffea arabica L. Extracts as a Novel Approach for the Treatment of Carbon Tetrachloride-Mediated Liver Fibrosis

Contact Info

Product

Resources

About